QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications.
The combination of QIAGEN's global reach and automation expertise with the assay development and manufacturing capabilities of ID Solutions will strengthen QIAGEN's position in oncology research.
Under the agreement, ID Solutions will manufacture and supply dPCR assays for non-clinical research use on QIAGEN's QIAcuity platforms. These assays are optimized to simultaneously detect multiple mutations in cell-free DNA (cfDNA) from plasma and genomic DNA (gDNA) from formalin-fixed, paraffin-embedded (FFPE) tissue. QIAGEN will commercialize these kits starting in Europe as the first region, with the potential for future expansion into other regions.
This agreement supports QIAGEN's strategic focus on accelerating the adoption of the QIAcuity dPCR platform in oncology research. The new assays expand QIAGEN's portfolio, complementing the existing PanCancer Kits for detecting multiple hallmark mutations in DNA from diverse sample types and over 200 LNA (locked nucleic acid) Mutation Assays available via its GeneGlobe platform. This unique platform integrates pre-designed assays with a database of more than 10,000 biological entities, including genes, miRNAs, pathogens and pathways.
"Through our collaboration with ID Solutions, we are reinforcing our commitment at QIAGEN to providing comprehensive dPCR solutions on QIAcuity that address critical needs in oncology research," said Simona Grandits, Vice President, Head of Commercial Operations for the Europe, Middle East and Africa (EMEA) Region at QIAGEN. "This agreement expands our assay portfolio, strengthens our position in oncology research, and supports faster, more reproducible results on the QIAcuity platform for our customers."
The partnership aligns with ID Solutions mission to develop its assays for research use only on fully integrated platforms. "Partnering with QIAGEN enables us to extend the reach of our high-quality dPCR assays to more laboratories," said Lise Grewis, CEO, ID Solutions. "Together, we're enabling faster adoption of dPCR in oncology research with robust, reliable results."
For customers, this partnership translates into streamlined access to ready-to-use assays optimized for QIAcuity in non-clinical oncology research, expanding beyond the current menu, enabling results in less than a day and meeting the growing demand for deeper molecular insights.
To learn more about QIAGEN's dPCR solutions and the new assays available through this partnership, visit https://www.id-solutions.fr/en/idnaptex-range/.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.
About ID Solutions
ID Solutions is a French company specialized in the development of molecular biology solutions for research and diagnostics in human oncology and infectious diseases. Founded in 2016 and based in Montpellier, ID Solutions has established capabilities for innovation, offering high-performance tools to support oncology departments across France. The company provides comprehensive solutions covering pre-analytical, analytical and interpretation stages, ensuring reliable, rapid and standardized molecular typing results. With a team of specialists in nucleic acid extraction, molecular biology and oncology, ID Solutions is committed to improving patient care through precision medicine and early detection of tumors. For more information, visit www.id-solutions.fr.
Forward-Looking Statement
Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Oncology
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
41 minutes ago
- Business Wire
Phenom Named Strategic Leader in Fosway 9-Grid™ for Talent Acquisition Fifth Consecutive Year
LONDON--(BUSINESS WIRE)-- Phenom, an applied AI company specialising in human resources, has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent Acquisition for the fifth year in a row. Phenom is the first Strategic Leader across all previous Talent Acquisition 9-Grids™ to receive the 'Excelling' trajectory assessment for two consecutive years — a distinction that underscores the company's accelerating innovation and market performance. 'Phenom is the first Strategic Leader across all previous Talent Acquisition 9-Grids™ that has been assessed as 'Excelling' in Trajectory for two consecutive years,' said Dr. Sven Elbert, Lead Analyst for Talent Acquisition, Fosway Group. Share Fosway Group evaluates vendors based on performance, potential, market presence, total cost of ownership, and trajectory. Phenom's position as a Strategic Leader reinforces its role in solving complex talent acquisition challenges — from attracting and engaging candidates to converting them into hires — by delivering AI, automation, and connected insights that drive real customer outcomes. 'Phenom is the first Strategic Leader across all previous Talent Acquisition 9-Grids™ that has been assessed as 'Excelling' in Trajectory for two consecutive years,' said Dr. Sven Elbert, Lead Analyst for Talent Acquisition, Fosway Group. 'With a focus on innovation and potential to serve enterprise customers effectively, Phenom continues to accelerate its performance and potential compared to both itself previously, as well as the wider market as a whole.' Built for Depth, Impact and Scalability Designed to meet the use case, compliance requirements, and complexity of global organisations, Phenom's integrated approach delivers deep functionality with AI and automation that addresses talent acquisition needs within the context of the organisation's greater goals. Phenom's pioneering 'Levels of automation' framework provides guided pathways for AI adoption, allowing organisations to start where they're comfortable and gradually advance their AI maturity — from basic automation to fully autonomous processes. This focus enables faster adoption, higher ROI and real-time alignment between hiring teams and business goals. Phenom's AI-driven platform ensures that every feature works together seamlessly to accelerate hiring, improve decision-making and deliver better experiences throughout the talent lifecycle. AI Innovation Driving Measurable Results Phenom continues to advance the industry's most comprehensive AI-powered Talent Experience platform. With innovations in Generative and Agentic AI for sourcing and screening to engaging and interviewing, Phenom is enabling employers to attract and hire talent more efficiently. Global customers have: 'Being recognised as the only Strategic Leader to achieve this level of momentum two years in a row — especially in a year that spotlights AI's role in talent acquisition — reflects how quickly and meaningfully our platform is advancing,' said Joanna Keel, Product Marketing Manager at Phenom. 'For TA teams, it means they can rely on Phenom to not only meet today's hiring demands, but also adapt to what's next with tools that reduce manual work, improve decision-making and create better experiences across the board.' Breakthrough AI for Every Talent Acquisition Challenge Seamlessly integrated with Phenom's award-winning Talent CRM and talent marketing capabilities, the platform's AI innovations enhance every stage of the hiring journey with automation and personalisation. These capabilities help teams move faster, reduce effort, and hire with confidence: Comprehensive talent relationship management with intelligent candidate recommendations, fit scoring, automated workflows, and personalised engagement campaigns Advanced sourcing and outreach using X+ Source to identify and engage quality candidates at scale AI-powered screening and interview tools that improve decision-making, reduce bias, and provide real-time insights Intelligent workflow automation for scheduling and candidate engagement Flexible hiring support for contingent workers, events, and executive recruitment scenarios In addition to a strong European presence, more than 700 companies around the world are successfully adopting Phenom's Intelligent Talent Experience platform to help candidates find and choose the right job faster, employees develop their skills and evolve, recruiters become highly productive, talent marketers engage with extreme efficiency, talent leaders optimise hiring and onboarding processes, managers build stronger-performing teams, HR aligns employee development with company goals, and HRIT easily integrates existing HR tech to create a holistic infrastructure. To learn more about Phenom's leadership position, read the report. To learn why Phenom continues to receive industry accolades, request a demo. About Phenom Phenom has a purpose of helping a billion people find the right work. Through AI-powered talent experiences, employers use Phenom to hire and onboard employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, talent marketers, talent leaders, hiring managers, HR and HRIT — empowering diverse and global enterprises with innovative products including Phenom X+ Agentic AI and Generative AI, Career Site, Chatbot, CMS, Talent CRM, X+ Screening, Automated Interview Scheduling, Interview Intelligence, Talent Experience Engine, Campaigns, University Recruiting, Contingent Talent Hiring, Onboarding, Talent Marketplace, Workforce Intelligence, Career Pathing, Gigs, Mentoring, and Referrals. Phenom has earned accolades including: Inc. 5000's fastest-growing companies (5 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), 11 Brandon Hall 'Excellence in Technology' awards including Gold for 'Best Advance in Generative AI for Business Impact,' Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), The Cloud Awards 2025/2024, The A.I. Awards 2024, and a regional Timmy Award for launching and optimising (2020). Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
Forbes
an hour ago
- Forbes
Wells Fargo Just Got Unshackled. What Next?
WASHINGTON, DC - MAY 31: A Wells Fargo logo is displayed on a sign at an ATM on May 31, 2025 in ... More Washington, DC. (Photo by) Wells Fargo (NYSE: WFC) stock has increased by 3% over the past week and is up nearly 9% year-to-date. The recent uptick follows the announcement from the U.S. Federal Reserve last week stating that Wells Fargo will no longer be bound by the $1.95 trillion asset cap enforced on the bank's operations due to its prolonged sales practices scandal. The Federal Reserve highlighted that Wells Fargo has made significant strides in rectifying its previous issues, especially in governance and risk management areas. The $1.95 trillion asset cap had compelled the bank to limit its lending and deposit acceptance, resulting in it falling considerably behind competitors like JPMorgan Chase, which currently holds over $4 trillion in assets. Consequently, Wells Fargo altered its strategy to concentrate on businesses that yield higher returns and are less capital-intensive, such as investment banking and advisory services. Although the cap restricted growth, it also motivated the bank to become leaner and more efficient, enhancing its emphasis on risk management and operational discipline. Now that the limitation is removed, Wells Fargo can expand its balance sheet and earnings by acquiring more commercial deposits, which offer less expensive and more stable funding sources that can lower overall capital costs. This could enable the bank to reinvest in areas that benefit from its larger balance sheet. Separately, if you are seeking upside potential with a more stable experience than an individual stock, consider the High Quality portfolio, which has outperformed the S&P and achieved >91% returns since inception. Wells Fargo's Q1 figures were mixed. Net income grew by 6% year-over-year to $4.89 billion, while revenue decreased by 3%. Net interest income, a measure of the earnings from lending activities, fell by 6% year-over-year to $11.50 billion. Noninterest income, which encompasses fees from investment banking, brokerage, and advisory services, rose by 1% to $8.65 billion compared to last year's $8.64 billion. The banking industry has generally adopted a cautious stance regarding the near-term outlook due to geopolitical uncertainties, the U.S. imposing tariffs on trading partners, and concerns about inflation. Fears of inflation have pushed Treasury yields higher, with the 10-year yield exceeding 4.40%, up from 4.01% in early April, while the yield on the 30-year bond stands just below 5%. This may yield mixed consequences for Wells Fargo. Rising rates and market fluctuations could negatively impact the investment banking sector, as these factors frequently result in delays in IPOs, mergers, and acquisition activities. However, on the lending front, higher yields increase the gap between what banks earn from loans and what they pay on deposits, generally improving net interest income and overall profitability, although they could also affect credit quality to some degree. We assess WFC stock to be worth around $71 per share, which is slightly under the current market valuation. Refer to Trefis' estimate for Wells Fargo's valuation.
Business Insider
an hour ago
- Business Insider
‘No Turnaround in Sight,' Says Wedbush About GameStop Stock
GameStop (NYSE:GME) is known for its fanbase of rabid retail investors, but the love is not one the company seems to reciprocate. For the past three years, the struggling video game retailer has failed to hold a conference call or provide guidance when releasing quarterly reports. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter With the company poised to report F1Q25 results tomorrow (June 10), Wedbush analyst Michael Pachter expects 'no improvement in their attitude toward investors.' But what about the actual results? For the quarter, Pachter expects net sales of $750 million, representing a 14.9% year-over-year drop, and EPS of $0.08. That compares to consensus expectations of $754 million and $0.04, respectively. Industry-wide, both hardware and software sales declined y/y, though software held up better thanks to a strong release lineup during the quarter. Hardware sales saw a sharp y/y downturn, largely because the PS5 and Xbox Series X/S have been on the market for several years now. However, Pachter expects hardware demand to rebound next quarter with the launch of the Switch 2. In Q1, profits should get a boost from a stronger software mix, while higher interest income – driven by recent share offerings – will help offset ongoing operating losses. Taking a leaf out of the MicroStrategy playbook, GameStop has also begun accumulating Bitcoin and now owns 4,710 BTC. That said, MicroStrategy trades at roughly 1.75 times the value of its Bitcoin holdings, indicating that investors assign it a premium beyond just its crypto assets. In comparison, GameStop trades at about 2.4 times the value of its cash, which now includes Bitcoin. This suggests investors are giving GameStop a similar kind of Bitcoin-related premium, even though its core retail business is being implicitly valued at just $8 per share. What Pachter finds 'baffling' is that GameStop's Bitcoin holdings are tiny compared to MicroStrategy's – just about 1% as much. Yet both stocks are receiving similar levels of crypto-related investor enthusiasm. While GameStop has seen some 'modest success' with its move into trading cards, Pachter thinks there's 'no potential for a rebound in GameStop's core business,' but that hasn't really mattered here. 'Despite a complete lack of an articulated strategy, GameStop has consistently been able to capitalize on the existence of 'greater fool' willing to pay more than twice its asset value for its shares—and so far, they've been right,' Pachter said. But in his view, GME shares are trading 'at a level that ignores the company's many challenges ahead.' As such, ahead of the print, Pachter rates GME shares an Underperform (i.e., Sell), along with a $13.5 price target, suggesting the shares will shed 54% of their value over the next year. (To watch Pachter's track record, click here) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
